Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II EVALUATION OF RECOMBINANT INTERFERON-ALPHA AND BCNU IN RECURRENT GLIOMA
Autore:
BUCKNER JC; BROWN LD; KUGLER JW; CASCINO TL; KROOK JE; MAILLIARD JA; KARDINAL CG; TSCHETTER LK; OFALLON JR; SCHEITHAUER BW;
Indirizzi:
MAYO CLIN & MAYO FDN,DEPT NEUROL,DIV MED ONCOL,CANC STAT UNIT,200 1STST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,SURG PATHOL SECT ROCHESTER MN 55905 IOWA ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM DES MOINES IA 00000 ILLINOIS ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM PEORIA IL 00000 DULUTH COMMUNITY CLIN ONCOL PROGRAM DULUTH MN 00000 CREIGHTON UNIV,NEBRASKA ONCOL GRP,UNIV NEBRASKA MED CTR & ASSOCIATES OMAHA NE 68178 OCHSNER COMMUNITY CLIN ONCOL PROGRAM NEW ORLEANS LA 00000 SIOUX COMMUNITY CANC CONSORTIUM COMMUNITY CLIN ON SIOUX FALLS SD 00000
Titolo Testata:
Journal of neurosurgery
fascicolo: 3, volume: 82, anno: 1995,
pagine: 430 - 435
SICI:
0022-3085(1995)82:3<430:PEORIA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT BRAIN-TUMORS; CARMUSTINE BCNU; CHEMOTHERAPY; NSC-409962; THERAPY;
Keywords:
BCNU; INTERFERON; ASTROCYTOMA; CHEMOTHERAPY; BRAIN NEOPLASM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
J.C. Buckner et al., "PHASE-II EVALUATION OF RECOMBINANT INTERFERON-ALPHA AND BCNU IN RECURRENT GLIOMA", Journal of neurosurgery, 82(3), 1995, pp. 430-435

Abstract

The goal of this study was to determine the antitumor activity and toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) plus recombinantinterferon-alpha (IFN-alpha) in patients with recurrent glioma. As single agents, both BCNU and IFN-alpha can cause tumor regression in patients with recurrent glioma. In vitro studies suggest synergy between the two agents. Thirty-five patients in whom computerized tomography (CT) or magnetic resonance (MR) evidence was obtained of progressive astrocytoma, oligoastrocytoma, or oligodendroglioma received recombinantIFN-alpha(2a) (12 X 10(6) U/m(2) intramuscularly) on Days 1 through 3and BCNU (150 mg/m(2) intravenously) on Day 3 of each 6-week cycle. All patients had tumor progression despite radiation therapy and had received no prior chemotherapy. Response was assessed by CT or MR evidence and by neurological examination while the patients were on a regimen of stable or decreasing doses of corticosteroids. All patients couldbe evaluated for response and toxicity. Twenty-nine percent of the patients demonstrated objective tumor regression; 37% remained stable for more than 6 months and 25% were stable for less than 6 months. The median duration of response to IFN-alpha and BCNU was 9.9 months and the median survival for all patients was 13.3 months. Toxicity consistedprimarily of moderate myelosuppression, venous irritation, vomiting, flulike symptoms, and transient reversible exacerbation of underlying neurological symptoms. The use of BCNU plus IFN-alpha is a safe, active regimen in the treatment of patients with recurrent glioma who have failed to respond to prior radiation therapy. The contribution of IFN to the antitumour activity observed in this study compared with that previously described with BCNU alone cannot be assessed from this trial.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 09:04:12